Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | WNT1 | P04628 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26742795 | 0.85 | KDM1A (0.39) | KDM1AEPHX1WNT1GSK3BDYRK1A | |
| SCHEMBL26741470 | 0.77 | HRH3 (0.46) | ALDH1A1TSHRHSD17B10 | |
| SCHEMBL10274873 | 0.76 | KEAP1 (0.48) | EPHX1 | |
| SCHEMBL12793976 | 0.75 | LTA4H (0.43) | KDM1AWNT1GSK3BDYRK1ASMN1; SMN2 | |
| SCHEMBL19022019 | 0.74 | EPHX1 (0.42) | EPHX1POLBKCNH2CACNA1ISMN1; SMN2 | |
| SCHEMBL26707996 | 0.73 | KCNH2 (0.39) | KDM1AEPHX1WNT1GSK3BDYRK1A | |
| SCHEMBL9911420 | 0.73 | TP53 (0.45) | KDM1AWNT1GSK3BDYRK1AALDH1A1 | |
| SCHEMBL25467851 | 0.72 | KDM1A (0.46) | KDM1AWNT1GSK3BDYRK1A | |
| SCHEMBL29339640 | 0.72 | WNT1 (0.43) | KDM1AWNT1GSK3BDYRK1AALDH1A1 | |
| SCHEMBL9911414 | 0.72 | LTA4H (0.47) | KDM1AWNT1GSK3BDYRK1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | KDM1A 1195/4885EPHX1 445/4885WNT1 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.